Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 3Phase 1/2 3Phase 1 1

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 133Carboplatin 132Cisplatin 119Paclitaxel 104Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 73Dexamethasone 60Cyclophosphamide 60Pemetrexed 57durvalumab 55Bevacizumab 55Capecitabine 54Radiotherapy 51Doxorubicin 51Oxaliplatin 50Fluorouracil 48Radiation 47Rituximab 43Leucovorin 43Vincristine 41Lenalidomide 40Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 32Bortezomib 31Prednisone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Ado-Trastuzumab Emtansine × 90 days × Clear all
NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

SWOG Cancer Research Network

Phase 3 Not yet recruiting
562 enrolled
Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡